

Easy to use. **Easy** to deploy.

Enhanced conformability


- Improved strut design for greater wall apposition

Ease of use

- Designed for delivery through an 0.0165in (Excelsior SL-10) or 0.017in (Excelsior XT-17) microcatheter
- Predictable stent re-crossability

High deployment accuracy

- Low foreshortening
- Superior radial force compared to closed cell and braided stents



Product information

Product number	Stent diameter	Stent length	Unconstrained stent diameter	Recommended parent vessel diameter
M003EZAS30150	3.0mm	15mm	3.5mm	≥2.0 and <3.0mm
M003EZAS30210	3.0mm	21mm	3.5mm	≥2.0 and <3.0mm
M003EZAS30240	3.0mm	24mm	3.5mm	≥2.0 and <3.0mm
M003EZAS40150	4.0mm	15mm	4.5mm	≥3.0 and <4.0mm
M003EZAS40240	4.0mm	24mm	4.5mm	≥3.0 and <4.0mm
M003EZAS45210	4.5mm	21mm	5.0mm	≥4.0 and <4.5mm
M003EZAS45300	4.5mm	30mm	5.0mm	≥4.0 and <4.5mm

Neuroform Atlas Stent System

See package insert for complete indications, contraindications, warnings and instructions for use.

Intended use/indications for use

The Neuroform Atlas Stent System is intended to be used with occlusive devices in the treatment of intracranial aneurysms.

Excelsior SL-10 Microcatheter

See package insert for complete indications, contraindications, warnings and instructions for use.

Intended use / indications for use

Stryker Neurovascular Excelsior SL-10 Microcatheter is intended to assist in the delivery of diagnostic agents, such as contrast media, and therapeutic agents, such as occlusion coils, into the peripheral, coronary, and neurovasculature.

Excelsior XT-17 Microcatheter


See package insert for complete indications, contraindications, warnings and instructions for use.

Intended use / indications for use

Stryker Neurovascular's Excelsior XT-17 Microcatheters are intended to assist in the delivery of diagnostic agents, such as contrast media, and therapeutic agents, such as occlusion coils, into the peripheral, coronary and neuro vasculature.

This document is intended solely for the use of healthcare professionals.

A physician must always rely on his or her own professional clinical judgment when deciding whether to use a particular product when treating a particular patient. Stryker does not dispense medical advice and recommends that physicians be trained in the use of any particular product before using it in a procedure. The information presented is intended to demonstrate the breadth of Stryker product offerings. A physician must always refer to the package insert, product label and/or instructions for use before using any Stryker product. Products may not be available in all markets because product availability is subject to the regulatory and/or medical practices in individual markets. Please contact your Stryker representative if you have questions about the availability of Stryker products in your area.



Neuroform Atlas™
Stent System

When outcomes matter most

stryker

Stryker or its affiliated entities own, use, or have applied for the following trademarks or service marks: Excelsior, Hydrolene, Neuroform, Neuroform EZ, Neuroform Atlas, Segmental, SL-10, Stryker, XT-17. All other trademarks are trademarks of their respective owners or holders.

The absence of a product, feature, or service name, or logo from this list does not constitute a waiver of Stryker's trademark or other intellectual property rights concerning that name or logo.

Copyright © 2020 Stryker
AP002758 v2.0

AUS Australian
Sponsor Address
Stryker Australia Pty Ltd
8 Herbert Street
St Leonards, NSW 2065
Australia


Stryker Neurovascular
47900 Bayside Parkway
Fremont, CA 94538
strykerneurovascular.com
Date of Release: MAY/2020
EX_EN_IL

The Atlas Study is the largest IDE of its class with 182 patients treated

84.7% Primary **efficacy** endpoint


Hybrid cell design

Hybrid cell structure designed to enhance stent opening and conformability




Improved wall apposition

Independent stent segments allow stent to conform to the vessel wall



Superior radial force

The high radial pressure of the Neuroform Atlas Stent may lead to greater stent stability



4.4% Primary **safety** endpoint

Low foreshortening

6.3% Average foreshortening for higher deployment accuracy


Low metal-to-artery ratio

6-12% Designed to leave less metal in the parent vessel

3.8% **Retreatment** rate


Segmental expansion

Segmental expansion of the stent enhances anchoring of the stent and promotes stent opening in tapered vessels



Improved scaffolding

Neuroform Atlas Stent cells are designed to have an improved coil scaffold while facilitating recrossability, compared to Neuroform EZ Stent cells



Neuroform Atlas™
Stent System

All photos and illustrations owned by Stryker.
Bench test results, n=1.
Bench test results may not necessarily be indicative of clinical performance.